We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE (endtxninHE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01446523
Recruitment Status : Completed
First Posted : October 5, 2011
Last Update Posted : April 10, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to examine S.endotoxins , inflammatory mediators and Magnetic Resonance Spectroscopy (MRS) before and after treatment in patients of cirrhosis and minimal hepatic encephalopathy.

Condition or disease Intervention/treatment
Hepatic Encephalopathy Drug: placebo Drug: Lactulose

Detailed Description:

60 patients of cirrhosis with Minimal Hepatic Encephalopathy (MHE) who fulfills the inclusion & exclusion criteria will be the part of study. Study patients will be divided in to two groups ( n=30 in each group).

Group L patients will receive lactulose therapy while Group NL will receive placebo. After 3 months , S.endotoxins , inflammatory mediators and MRS will be repeated in each group.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Serum Endotoxins, Inflammatory Mediators and MR Spectroscopy Before and After Treatment in Minimal Hepatic Encephalopathy
Study Start Date : October 2011
Primary Completion Date : February 2012
Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Lactulose
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: Lactulose
Group L receives lactulose Group NL receives placebo
Drug: Lactulose
Syrup 30 ml BD for 12 weeks
Other Name: Duphalac , Looz
Placebo Comparator: Placebo
Group NL receives placebo
Drug: placebo
Syrup, 30 ml BD for 3 months in Gr. NL


Outcome Measures

Primary Outcome Measures :
  1. Improvement of minimal hepatic encephalopathy [ Time Frame: Baseline and at 12 weeks ]

Secondary Outcome Measures :
  1. correlation between inflammatory mediators and grades of encephalopathy [ Time Frame: Baseline and at 12 weeks ]
    To measure values of inflammatory mediators in different grades of encephalopathy


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Cirrhosis (Age 15 yr -70 yr )

Exclusion Criteria:

  • Recent history of gastrointestinal bleed in last 6 weeks
  • Active ongoing infection
  • Creatinine >1.5mg%
  • Electrolyte impairment. (S. Sodium < 130 meq/L, S. Potassium 3.5 meq/L or >5.0meq/L)
  • H/O use of psychotropic drugs in last 6 weeks
  • Recent alcohol use (< 6 week )
  • H/O TIPS or shunt surgery.
  • Hepatocellular Carcinoma
  • Severe comorbidity as Congestive Heart Failure, Pulmonary disease, Neurological and Psychiatric problems impairing quality of life
  • Poor vision precluding neuropsychological assessment
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01446523


Locations
India
BC Sharma
New Delhi, Delhi, India, 110060
Sponsors and Collaborators
Govind Ballabh Pant Hospital
Investigators
Principal Investigator: Barjesh c Sharma, DM GB Pant Hospital
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Barjesh Chander Sharma, Professor, Govind Ballabh Pant Hospital
ClinicalTrials.gov Identifier: NCT01446523     History of Changes
Other Study ID Numbers: endotoxins in MHE
First Posted: October 5, 2011    Key Record Dates
Last Update Posted: April 10, 2012
Last Verified: April 2012

Keywords provided by Barjesh Chander Sharma, Govind Ballabh Pant Hospital:
endotoxins HE

Additional relevant MeSH terms:
Brain Diseases
Hepatic Encephalopathy
Central Nervous System Diseases
Nervous System Diseases
Liver Failure
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases
Brain Diseases, Metabolic
Metabolic Diseases
Lactulose
Gastrointestinal Agents